Bio Techne Corp Stock Performance
| TECH Stock | USD 75.01 0.24 0.32% |
Bio Techne has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.83, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bio Techne's returns are expected to increase less than the market. However, during the bear market, the loss of holding Bio Techne is expected to be smaller as well. Bio Techne Corp right now shows a risk of 2.22%. Please confirm Bio Techne Corp expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Bio Techne Corp will be following its price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bio Techne Corp are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly strong fundamental indicators, Bio Techne is not utilizing all of its potentials. The recent stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return (0.32) | Five Day Return 2.75 | Year To Date Return 4.94 | Ten Year Return 234.12 | All Time Return 68.5 K |
Forward Dividend Yield 0.0044 | Payout Ratio | Last Split Factor 4:1 | Forward Dividend Rate 0.32 | Dividend Date 2025-02-28 |
| Bio Techne dividend paid on 22nd of November 2024 | 11/22/2024 |
1 | Techne Up 2.2 percent Since Last Earnings Report Can It Continue | 11/29/2024 |
2 | BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE | 12/20/2024 |
3 | Heres Why Bio-Techne Can Manage Its Debt Responsibly | 01/21/2025 |
4 | Fort Washington Investment Advisors Inc. OH Boosts Holdings in Bio-Techne Co. | 01/23/2025 |
5 | Would a Tory-Reform electoral pact really be unassailable | 01/24/2025 |
6 | Disposition of 13392 shares by Kim Kelderman of Bio Techne at 37.7 subject to Rule 16b-3 | 01/27/2025 |
7 | Bio-Techne CEO Kim Kelderman sells 1.04 million in stock - MSN | 01/30/2025 |
8 | Reform UK pips Labour in YouGov voter poll for first time | 02/03/2025 |
9 | Bio-Techne signals high single-digit growth recovery by Q4 2025, driven by biopharma momentum | 02/05/2025 |
| Begin Period Cash Flow | 180.6 M |
Bio |
Bio Techne Relative Risk vs. Return Landscape
If you would invest 7,469 in Bio Techne Corp on November 9, 2024 and sell it today you would earn a total of 32.00 from holding Bio Techne Corp or generate 0.43% return on investment over 90 days. Bio Techne Corp is currently generating 0.0317% in daily expected returns and assumes 2.222% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than Bio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bio Techne Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio Techne's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bio Techne Corp, and traders can use it to determine the average amount a Bio Techne's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0142
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TECH |
Estimated Market Risk
| 2.22 actual daily | 19 81% of assets are more volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Bio Techne is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio Techne by adding it to a well-diversified portfolio.
Bio Techne Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Techne, and Bio Techne fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
| Return On Equity | 0.0729 | ||||
| Return On Asset | 0.0555 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 12.17 B | ||||
| Shares Outstanding | 158.89 M | ||||
| Price To Earning | 74.38 X | ||||
| Price To Book | 5.75 X | ||||
| Price To Sales | 10.17 X | ||||
| Revenue | 1.16 B | ||||
| Gross Profit | 773.94 M | ||||
| EBITDA | 310.37 M | ||||
| Net Income | 168.07 M | ||||
| Cash And Equivalents | 247.03 M | ||||
| Cash Per Share | 6.30 X | ||||
| Total Debt | 419.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.44 X | ||||
| Book Value Per Share | 13.08 X | ||||
| Cash Flow From Operations | 298.98 M | ||||
| Earnings Per Share | 0.98 X | ||||
| Market Capitalization | 11.92 B | ||||
| Total Asset | 2.7 B | ||||
| Retained Earnings | 1.33 B | ||||
| Working Capital | 458.04 M | ||||
| Current Asset | 253.89 M | ||||
| Current Liabilities | 54.15 M | ||||
About Bio Techne Performance
By evaluating Bio Techne's fundamental ratios, stakeholders can gain valuable insights into Bio Techne's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bio Techne has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bio Techne has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 151.65 | 85.43 | |
| Return On Tangible Assets | 0.12 | 0.16 | |
| Return On Capital Employed | 0.09 | 0.09 | |
| Return On Assets | 0.07 | 0.07 | |
| Return On Equity | 0.09 | 0.09 |
Things to note about Bio Techne Corp performance evaluation
Checking the ongoing alerts about Bio Techne for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio Techne Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: Bio-Techne signals high single-digit growth recovery by Q4 2025, driven by biopharma momentum |
- Analyzing Bio Techne's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Techne's stock is overvalued or undervalued compared to its peers.
- Examining Bio Techne's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio Techne's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Techne's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio Techne's stock. These opinions can provide insight into Bio Techne's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bio Stock analysis
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |